"As value-based health technology assessment is gradually gaining acceptance, robust evidence is required to map the value of a product against patients’ overall well-being in real-world settings. High quality real-world data could fill this evidence gap between the information required for decision making by different stakeholders and could provide an opportunity to pharma companies to expedite their market access goals. However, despite the clear advantages, the real-world evidence has varying degree of acceptability due to scepticism about its robustness. Therefore, attempts are being made to implement good reporting and analysis practice to help draw credible inferences from real-world data."

Dr. Vatsal Shah

Chief Operating Officer



quit
Dr. Rishabh Pandey

Rishabh Pandey holds a doctorate in Pharmacology trained at the Indian Institute of Public Health on conducting meta-analysis and health economic evaluations and has also been certified on health technology assessments by the University of Sheffield. He has published & presented more than 30 papers in national/international journals & conferences and reviewed manuscripts for leading publication houses like Elsevier, SAGE, Bentham science, Springer and Informa.

His experience spans over a decade including academics, scientific communications and medical information. He has worked on numerous public health, epidemiology, real world evidence, health economics and outcome research projects.

He was part of GSK’s Global Medical Information and Scientific Affairs Department (GMISA) before he began his stint at SIRO. In his +4 years at SIRO, he has worked on more than 60 publications spanning various TAs like oncology, neurosciences, cardiovascular & outcome research for internationally reputed journals and international congresses.

Dr. Rishabh Pandey


Rishabh Pandey holds a doctorate in Pharmacology trained at the Indian Institute of Public Health on conducting meta-analysis and health economic evaluations and has also been certified on health technology assessments by the University of Sheffield. He has published & presented more than 30 papers in national/international journals & conferences and reviewed manuscripts for leading publication houses like Elsevier, SAGE, Bentham science, Springer and Informa.

His experience spans over a decade including academics, scientific communications and medical information. He has worked on numerous public health, epidemiology, real world evidence, health economics and outcome research projects.
Read more


"The reporting quality of pharmacoeconomic studies before and after publication of the CHEERS checklist"




Research Poster Presentation:


Research on methods - Session I
Monday, May 21, 2018: 8:30 AM - 2:00 PM
Poster Discussion: 13:00 - 14:00

The cost of cancer treatments is increasing faster than the consumer price index. Therefore, generation and reporting of quality pharmacoeconomic studies is important to determine the value of treatments. Our experts assessed the reporting quality of published pharmacoeconomic studies of hematologic malignancies using the widely accepted 24-item CHEERS checklist.


"Developing a consolidated checklist (stRWE-retro) to assess the reporting quality of real world evidence studies based on retrospective data analyses"


Research Poster Presentation:


Research on methods - Session I
Monday, May 21, 2018: 8:30 AM - 2:00 PM
Poster Discussion: 13:00 - 14:00

Retrospective data analysis (RDA) is the most common design of real world evidence (RWE) studies. The available recommendations for RDA are either focused on methodological quality or generalized for all designs of observational studies. Rishabh will be discussing a consolidated checklist, StRWE-Retro, constructed to standardize the reporting of RDA. The StRWE-Retro checklist showed good internal consistency. He will also be discussing how this checklist can help publication writers improve the quality of RDA reporting on validation by a larger panel of experts.


"Efficacy and inhibitor development of prophylactic vs on-demand Factor VIII and IX in the management of haemophilia patients from Southeast Asia: a systematic review"


Research Poster Presentation:


Systemic disorders/conditions - Session V
Wednesday, May 23, 2018: 8:30 AM - 1:30 PM
Poster Discussion: 12:30 - 13:30

Prophylactic treatment of patients with hemophilia using factor VIII and IX infusions is considered to be a standard approach of care by World Federation of Hemophilia. However, hemophilia patients from Southeast Asian countries have to rely on ‘on-demand’ therapy due to high out-of-pocket expenses associated with prophylactic therapy. Rishabh, in his study, conducted a systematic review to compare the efficacy with prophylactic and on-demand factor VIII and IX therapy in hemophilia patients from Southeast Asia to address the need of evidence based reimbursement decision making in hemophilia. Risk of inhibitor development against both therapies was also compared.




SCIENTIFIC WRITING AND PUBLICATIONS

“SIRO drives its wheel of progress in varied arenas of scientific and medical publications with its well-trained, process-compliant, customer-centric team of publication specialists”